Linxinyu Xu

High‐mobility group box‐1 and its role in angiogenesis

Tianshu Yang, Shuai Yang, Linxinyu Xu, 2014, Journal of leukocyte biology.

Subretinal injection of amyloid-β peptide accelerates RPE cell senescence and retinal degeneration.

Shuai Yang, Linxinyu Xu, F. Wang, 2015, International journal of molecular medicine.

Sintilimab for relapsed/refractory (r/r) extranodal NK/T cell lymphoma (ENKTL): Extended follow-up on the multicenter, single-arm phase II trail (ORIENT-4).

Jian-yong Li, Linxinyu Xu, Yongping Song, 2020 .

A first-in-human phase 1a trial of sintilimab (IBI308), a monoclonal antibody targeting programmed death-1 (PD-1), in Chinese patients with advanced solid tumors.

Jianming Xu, Xuan Kong, Linxinyu Xu, 2018 .

Sintilimab in patients with advanced esophageal squamous cell carcinoma refractory to previous chemotherapy: A randomized, open-label phase II trial (ORIENT-2).

N. Xu, Jianming Xu, Yunpeng Liu, 2020 .

Sintilimab for relapsed/refractory (r/r) extranodal NK/T-cell lymphoma (ENKTL): A multicenter, single-arm, phase 2 trial (ORIENT-4).

Linxinyu Xu, Yongping Song, Yu Hu, 2019, Journal of Clinical Oncology.

Epo inhibits the fibrosis and migration of Müller glial cells induced by TGF-β and high glucose

F. Wang, Guotong Xu, Weiye Li, 2016, Graefe's Archive for Clinical and Experimental Ophthalmology.

Sintilimab for Relapsed/Refractory Extranodal NK/T-Cell Lymphoma: A Multicenter, Single-Arm, Phase 2 Trial (ORIENT-4)

Linxinyu Xu, Yongping Song, Yu Hu, 2020 .